Amyris Inc (AMRSQ)

[seasonedwell]

It's imprudent to short this stock......

Shares are funding at 1.40 and previous funding came in at 1.14 from Bill and Melinda Gates...Bill and Melinda just came up with more money at 1.14 and is giving grants through the Gates Foundation. And Amyris is doing work that Bill and Melinda want done.

[Amyris’s first major milestone came in 2005 when, through a grant from the Bill & Melinda Gates Foundation, our scientists developed technology capable of creating microbial strains to produce artemisinic acid — a precursor of artemisinin, an effective anti-malarial drug.

Then there is the Singapore government with 74,725,122 shares here....

Temasek, through its ownership of FMPL, may be deemed to share voting and dispositive power over the 74,725,122 shares of Common Stock beneficially owned or deemed to be beneficially owned by FMPL, Cairnhill and Maxwell.

Amyris expects to receive cash representing a short-term collaboration investment of $10 million, an equity investment of up to $20 million at $1.40 per share, $100 million in annual revenue starting in 2017 connected to the production and cost improvement of fermentation molecules, and participation in the partner's industrial fermentation facilities in Asia.

As previously reported, on April 8, 2016, Amyris, Inc. (the “ Company ”) and the Bill & Melinda Gates Foundation (the “ Gates Foundation ”) entered into (i) a Securities Purchase Agreement (the “ Purchase Agreement ”), pursuant to which the Company agreed to sell and issue 4,385,964 shares of its common stock (the “ Shares ”) to the Gates Foundation at a purchase price per share equal to $1.14 (the “ Gates Foundation Investment ”) and (ii) a Charitable Purposes Letter Agreement (the “ Letter Agreement ”), pursuant to which the Company agreed to use the proceeds from the Gates Foundation Investment to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. The entry into the Purchase Agreement and the Letter Agreement was previously reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 11, 2016, which is incorporated herein by reference.

As previously reported, on April 8, 2016, Amyris, Inc. (the “ Company ”) and the Bill & Melinda Gates Foundation (the “ Gates Foundation ”) entered into (i) a Securities Purchase Agreement (the “ Purchase Agreement ”), pursuant to which the Company agreed to sell and issue 4,385,964 shares of its common stock (the “ Shares ”) to the Gates Foundation at a purchase price per share equal to $1.14 (the “ Gates Foundation Investment ”) and (ii) a Charitable Purposes Letter Agreement (the “ Letter Agreement ”), pursuant to which the Company agreed to use the proceeds from the Gates Foundation Investment to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. The entry into the Purchase Agreement and the Letter Agreement was previously reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 11, 2016, which is incorporated herein by reference.

On May 10, 2016, the Company and the Gates Foundation closed the Gates Foundation Investment, resulting in the issuance of 4,385,964 Shares to the Gates Foundation for proceeds to the Company of approximately $5.0 million.